Vol. 2 No. 2 (2022)
Reimbursement Reviews

Zanubrutinib (Brukinsa)

Published February 7, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses zanubrutinib (Brukinsa), 80 mg oral capsules.
  • Indication: Treatment of adult patients with Waldenström macroglobulinemia (lymphoplasmacytic lymphoma).